RadioMedix

RadioMedix, Inc. is a clinical-stage biotechnology company based in Houston and Humble, Texas. The company focuses on developing innovative targeted radiopharmaceuticals for the diagnosis, monitoring, and therapy of cancer. RadioMedix specializes in radiopharmaceuticals for positron emission tomography (PET) imaging and targeted alpha and beta therapies.

In September 2020, the company received US FDA approval for its diagnostic product 64Cu-DOTATATE (DetectNET), a copper-64 based agent for neuroendocrine cancers. RadioMedix is also sponsoring a phase 2 clinical trial evaluating 212Pb-DOTAMTATE (AlphaMedix), a targeted alpha therapy for treating metastatic or inoperable neuroendocrine cancer. Patient enrollment for this trial has been completed, with top line data expected in mid-2024. Notably, the trial has already achieved its target objective response rate, more than twice the current standard of care.

In February 2023, RadioMedix partnered with Fusion Pharmaceuticals to advance the development of 225Ac-PSMA I&T, a targeted alpha therapy for metastatic castration-resistant prostate cancer. This program, now known as FPI-2265, was previously being evaluated in an ongoing phase 2 trial sponsored by RadioMedix.

The company has established comprehensive facilities, including a drug discovery center, a preclinical core facility, and a 27,500 sq ft cGMP manufacturing and analytical suite called the Spica Center for clinical trials and commercial manufacturing.

Key customers and partnerships

In October 2022, RadioMedix secured a USD 40 million Series A financing from an entity related to Portland Investment Counsel Inc. As part of the deal, Michael Lee-Chin, the founder and CEO of Portland, joined RadioMedix's board of directors.

RadioMedix has a long-standing partnership with ITM Isotopen Technologien München (ITM), a radiopharmaceutical company based in Germany. In 2023, the two companies announced an agreement for RadioMedix to manufacture ITM's Ge-68/Ga-68 generators at the Spica Center, addressing the global supply shortage of Ga-68 generators used in targeted radionuclide therapy.